Brain Injury Clinical Trial
Official title:
High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study
The highest risk for perinatal brain injury occurs among extremely premature infants who weigh less than 1250 grams at birth. Such perinatal brain injury is currently irreversible, associated with neurodevelopmental disability, and without adequate treatment modalities. Research in recent years suggest in both animal and human studies that erythropoietin (Epo) may have significant neuroprotective effects. Given the historical safe medical profile of Epo when used for anemia of prematurity but the likely need for a greater dosage regimen for activation of neuroprotective pathways against neonatal brain injury, we therefore propose this phase II study of high-dose Epo in very low birth weight infants for the prevention and/or attenuation of prematurity-related cerebral hemorrhagic-ischemic injury.
Eligible extremely premature infants will be enrolled in this double-blind,
placebo-controlled randomized trial from the neonatal intensive care unit at Morristown
Memorial Hospital (Morristown, New Jersey). Subjects will be enrolled within the first 24
hours of life and randomly assigned to receive Epo or saline vehicle placebo.
Standard NICU care will be provided to all subjects. Serial exams, CBC-d, reticulocyte
counts, serum Epo levels, serial HUS, and head MRI will be collected at established time
points during the study period. At 18 to 22 months corrected age, subjects will undergo a
neurodevelopmental evaluation assessing for cerebral palsy, Bayley Scores of Infant
Development-II (BSID-II) Mental Development Index (MDI), BSID-II Psychomotor Development
Index (PDI), bilateral hearing aid use, and visual impairment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02710123 -
Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion
|
N/A | |
Recruiting |
NCT02777060 -
Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures
|
N/A | |
Completed |
NCT02262286 -
MIND (Management of Traumatic Brain Injury Diagnosis)
|
N/A | |
Completed |
NCT01461902 -
Vasospasm in Pediatric Traumatic Brain Injury
|
N/A | |
Recruiting |
NCT01198964 -
Optimization of Human Cortical Stimulation
|
||
Active, not recruiting |
NCT01207050 -
Effect of Rozerem on Sleep Among People With Traumatic Brain Injury
|
Phase 4 | |
Completed |
NCT01201863 -
Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy
|
Phase 4 | |
Completed |
NCT00875329 -
Traumatic Brain Injury (TBI) Screening Instruments
|
N/A | |
Completed |
NCT01059890 -
Cerebral Antibiotics Distribution After Acute Brain Injury
|
Phase 1 | |
Completed |
NCT01035606 -
Training in Goal-directed Attention Regulation for Individuals With Brain Injury
|
N/A | |
Completed |
NCT00571623 -
Automated Chest Physiotherapy to Improve Outcomes in Neuro
|
N/A | |
Completed |
NCT00596765 -
Neuropsychological Cognitive Behavioral Therapy for Patients With Acquired Brain Injury
|
N/A | |
Completed |
NCT00336466 -
The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)
|
Phase 2 | |
Recruiting |
NCT05105763 -
Biofeedback Gait Retraining for Stiff Knee Gait Correction
|
N/A | |
Recruiting |
NCT02495558 -
Cough Assessment in Patients With Severe Acquired Brain Injury
|
N/A | |
Completed |
NCT02100592 -
Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study
|
Phase 1/Phase 2 | |
Completed |
NCT00797680 -
Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest
|
Phase 2 | |
Completed |
NCT00018499 -
Genotype Influence on Recovery After Traumatic Brain Injury
|
N/A | |
Recruiting |
NCT02567201 -
Electrophysiological Evaluation of Voluntary Attention
|
N/A | |
Withdrawn |
NCT05581927 -
Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE)
|
N/A |